| Autor: |
Keely SJ; Molecular Medicine Laboratories, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland., Walters JR; Division of Digestive Diseases, Hammersmith Hospital, Imperial College London, London, United Kingdom. |
| Jazyk: |
angličtina |
| Zdroj: |
Cellular and molecular gastroenterology and hepatology [Cell Mol Gastroenterol Hepatol] 2016 Aug 29; Vol. 2 (6), pp. 725-732. Date of Electronic Publication: 2016 Aug 29 (Print Publication: 2016). |
| DOI: |
10.1016/j.jcmgh.2016.08.004 |
| Abstrakt: |
Diarrhea is a feature of several chronic intestinal disorders that are associated with increased delivery of bile acids into the colon. Although the prevalence of bile acid diarrhea is high, affecting approximately 1% of the adult population, current therapies often are unsatisfactory. By virtue of its capacity to inhibit colonic epithelial fluid secretion and to down-regulate hepatic bile acid synthesis through induction of the ileal fibroblast growth factor 19 release, the nuclear bile acid receptor, farnesoid X receptor, represents a promising target for the development of new therapeutic approaches. Here, we review our current understanding of the pathophysiology of bile acid diarrhea and the current evidence supporting a role for farnesoid X receptor agonists in treatment of the disease. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
